Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 174

1.

Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer.

Ma L, Hernandez MO, Zhao Y, Mehta M, Tran B, Kelly M, Rae Z, Hernandez JM, Davis JL, Martin SP, Kleiner DE, Hewitt SM, Ylaya K, Wood BJ, Greten TF, Wang XW.

Cancer Cell. 2019 Oct 14;36(4):418-430.e6. doi: 10.1016/j.ccell.2019.08.007. Epub 2019 Oct 3.

2.

A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer.

Floudas CS, Brar G, Mabry-Hrones D, Duffy AG, Wood B, Levy E, Krishnasamy V, Fioravanti S, Bonilla CM, Walker M, Morelli MP, Kleiner DE, Steinberg SM, Figg WD, Greten TF, Xie C.

Clin Colorectal Cancer. 2019 Jul 2. pii: S1533-0028(19)30243-9. doi: 10.1016/j.clcc.2019.06.004. [Epub ahead of print]

3.

Establishment of Orthotopic Liver Tumors by Surgical Intrahepatic Tumor Injection in Mice with Underlying Non-Alcoholic Fatty Liver Disease.

Brown ZJ, Heinrich B, Greten TF.

Methods Protoc. 2018 Jun 4;1(2). pii: E21. doi: 10.3390/mps1020021.

4.

The effects of platelet accumulation in fatty liver disease.

Diggs LP, Greten TF.

Nat Rev Gastroenterol Hepatol. 2019 Jul;16(7):393-394. doi: 10.1038/s41575-019-0160-8. No abstract available.

PMID:
31114057
5.

Gender disparity in HCC: Is it the fat and not the sex?

Greten TF.

J Exp Med. 2019 May 6;216(5):1014-1015. doi: 10.1084/jem.20190441. Epub 2019 Apr 18.

6.

Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy.

Brown ZJ, Greten TF, Heinrich B.

Hepatology. 2019 Oct;70(4):1437-1442. doi: 10.1002/hep.30633. Epub 2019 Sep 19. Review.

PMID:
30927283
7.

Immunotherapy: Current Status and Future Perspectives.

Floudas CS, Brar G, Greten TF.

Dig Dis Sci. 2019 Apr;64(4):1030-1040. doi: 10.1007/s10620-019-05516-7. Review.

PMID:
30830521
8.

Combined locoregional-immunotherapy for liver cancer.

Greten TF, Mauda-Havakuk M, Heinrich B, Korangy F, Wood BJ.

J Hepatol. 2019 May;70(5):999-1007. doi: 10.1016/j.jhep.2019.01.027. Epub 2019 Feb 7. Review.

PMID:
30738077
9.

The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma.

Agdashian D, ElGindi M, Xie C, Sandhu M, Pratt D, Kleiner DE, Figg WD, Rytlewski JA, Sanders C, Yusko EC, Wood B, Venzon D, Brar G, Duffy AG, Greten TF, Korangy F.

Cancer Immunol Immunother. 2019 Apr;68(4):599-608. doi: 10.1007/s00262-019-02299-8. Epub 2019 Jan 28.

10.

Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer.

Xie C, Duffy AG, Mabry-Hrones D, Wood B, Levy E, Krishnasamy V, Khan J, Wei JS, Agdashian D, Tyagi M, Gangalapudi V, Fioravanti S, Walker M, Anderson V, Venzon D, Figg WD, Sandhu M, Kleiner DE, Morelli MP, Floudas CS, Brar G, Steinberg SM, Korangy F, Greten TF.

Hepatology. 2019 May;69(5):2048-2060. doi: 10.1002/hep.30482. Epub 2019 Mar 10.

PMID:
30578687
11.

Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.

Yu SJ, Ma C, Heinrich B, Brown ZJ, Sandhu M, Zhang Q, Fu Q, Agdashian D, Rosato U, Korangy F, Greten TF.

J Hepatol. 2019 Mar;70(3):449-457. doi: 10.1016/j.jhep.2018.10.040. Epub 2018 Nov 9.

PMID:
30414862
12.

Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy.

Brar G, Greten TF, Brown ZJ.

Therap Adv Gastroenterol. 2018 Oct 25;11:1756284818808086. doi: 10.1177/1756284818808086. eCollection 2018. Review.

13.

Development of shellfish allergy after exposure to dual immune checkpoint blockade.

Brown ZJ, Heinrich B, Greten TF.

Hepat Oncol. 2018 Feb 9;5(1):HEP02. doi: 10.2217/hep-2017-0021. eCollection 2018 Jan.

14.

Targeted and Immune-Based Therapies for Hepatocellular Carcinoma.

Greten TF, Lai CW, Li G, Staveley-O'Carroll KF.

Gastroenterology. 2019 Jan;156(2):510-524. doi: 10.1053/j.gastro.2018.09.051. Epub 2018 Oct 1. Review.

PMID:
30287171
15.

miR-130a and miR-145 reprogram Gr-1+CD11b+ myeloid cells and inhibit tumor metastasis through improved host immunity.

Ishii H, Vodnala SK, Achyut BR, So JY, Hollander MC, Greten TF, Lal A, Yang L.

Nat Commun. 2018 Jul 4;9(1):2611. doi: 10.1038/s41467-018-05023-9.

16.

Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma.

Brown ZJ, Yu SJ, Heinrich B, Ma C, Fu Q, Sandhu M, Agdashian D, Zhang Q, Korangy F, Greten TF.

Cancer Immunol Immunother. 2018 Aug;67(8):1305-1315. doi: 10.1007/s00262-018-2190-4. Epub 2018 Jun 29.

17.

Mitophagy in Intestinal Epithelial Cells Triggers Adaptive Immunity during Tumorigenesis.

Ziegler PK, Bollrath J, Pallangyo CK, Matsutani T, Canli Ö, De Oliveira T, Diamanti MA, Müller N, Gamrekelashvili J, Putoczki T, Horst D, Mankan AK, Öner MG, Müller S, Müller-Höcker J, Kirchner T, Slotta-Huspenina J, Taketo MM, Reinheckel T, Dröse S, Larner AC, Wels WS, Ernst M, Greten TF, Arkan MC, Korn T, Wirth D, Greten FR.

Cell. 2018 Jun 28;174(1):88-101.e16. doi: 10.1016/j.cell.2018.05.028. Epub 2018 Jun 14.

18.

Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research.

Brown ZJ, Heinrich B, Greten TF.

Nat Rev Gastroenterol Hepatol. 2018 Sep;15(9):536-554. doi: 10.1038/s41575-018-0033-6. Review.

PMID:
29904153
19.

Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells.

Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M, Agdashian D, Terabe M, Berzofsky JA, Fako V, Ritz T, Longerich T, Theriot CM, McCulloch JA, Roy S, Yuan W, Thovarai V, Sen SK, Ruchirawat M, Korangy F, Wang XW, Trinchieri G, Greten TF.

Science. 2018 May 25;360(6391). pii: eaan5931. doi: 10.1126/science.aan5931.

20.

Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4+ T cell apoptosis promoting HCC development.

Brown ZJ, Fu Q, Ma C, Kruhlak M, Zhang H, Luo J, Heinrich B, Yu SJ, Zhang Q, Wilson A, Shi ZD, Swenson R, Greten TF.

Cell Death Dis. 2018 May 23;9(6):620. doi: 10.1038/s41419-018-0687-6.

21.

Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients.

Khanna S, Graef S, Mussai F, Thomas A, Wali N, Yenidunya BG, Yuan C, Morrow B, Zhang J, Korangy F, Greten TF, Steinberg SM, Stetler-Stevenson M, Middleton G, De Santo C, Hassan R.

Clin Cancer Res. 2018 Jun 15;24(12):2859-2872. doi: 10.1158/1078-0432.CCR-17-3757. Epub 2018 Mar 30.

22.

The ABC of adaptive immunity in liver cancer.

Greten TF.

Hepatology. 2018 Aug;68(2):777-779. doi: 10.1002/hep.29839. Epub 2018 May 14. No abstract available.

23.

Single-cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma.

Zheng H, Pomyen Y, Hernandez MO, Li C, Livak F, Tang W, Dang H, Greten TF, Davis JL, Zhao Y, Mehta M, Levin Y, Shetty J, Tran B, Budhu A, Wang XW.

Hepatology. 2018 Jul;68(1):127-140. doi: 10.1002/hep.29778. Epub 2018 May 9.

24.

Research priorities for the discovery of a cure for chronic hepatitis B: Report of a workshop.

Block TM, Alter H, Brown N, Brownstein A, Brosgart C, Chang KM, Chen PJ, Cohen C, El-Serag H, Feld J, Gish R, Glenn J, Greten TF, Guo JT, Hoshida Y, Kowdley KV, Li W, Lok AS, McMahon B, Mehta A, Perrillo R, Rice CM, Rinaudo J, Schinazi RF, Shetty K.

Antiviral Res. 2018 Feb;150:93-100. doi: 10.1016/j.antiviral.2017.12.006. Epub 2017 Dec 14.

25.

Cellular senescence associated immune responses in liver cancer.

Greten TF, Eggert T.

Hepat Oncol. 2017 Oct;4(4):123-127. doi: 10.2217/hep-2017-0011. Epub 2017 Nov 17. Review.

26.

Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer.

Brown ZJ, Heinrich B, Steinberg SM, Yu SJ, Greten TF.

J Immunother Cancer. 2017 Nov 21;5(1):93. doi: 10.1186/s40425-017-0298-2.

27.

Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma.

Gerbes A, Zoulim F, Tilg H, Dufour JF, Bruix J, Paradis V, Salem R, Peck-Radosavljevic M, Galle PR, Greten TF, Nault JC, Avila MA.

Gut. 2018 Feb;67(2):380-388. doi: 10.1136/gutjnl-2017-315068. Epub 2017 Nov 17. Erratum in: Gut. 2018 Mar;67(3):594.

28.

Does CSF1R Blockade Turn into Friendly Fire?

Greten TF.

Cancer Cell. 2017 Nov 13;32(5):546-547. doi: 10.1016/j.ccell.2017.10.012.

29.

CDK20 inhibition and immune checkpoint blockade: bringing cancer biology and tumour immunology together to develop novel treatment options for HCC.

Greten TF, Korangy F.

Gut. 2018 May;67(5):783-784. doi: 10.1136/gutjnl-2017-315091. Epub 2017 Oct 24. No abstract available.

30.

Targets for immunotherapy of liver cancer.

Greten TF, Sangro B.

J Hepatol. 2017 Sep 18. pii: S0168-8278(17)32287-0. doi: 10.1016/j.jhep.2017.09.007. [Epub ahead of print] Review.

31.

Nonalcoholic fatty liver disease promotes hepatocellular carcinoma through direct and indirect effects on hepatocytes.

Ma C, Zhang Q, Greten TF.

FEBS J. 2018 Feb;285(4):752-762. doi: 10.1111/febs.14209. Epub 2017 Sep 15. Review.

32.

Commensal bacteria (ab)use CD8+ T cells to induce insulin resistance.

Ma C, Greten TF.

Sci Immunol. 2017 Apr 21;2(10). pii: eaan1473. doi: 10.1126/sciimmunol.aan1473. Review.

PMID:
28738021
33.

Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma.

Eggert T, Greten TF.

Digestion. 2017;96(1):1-4. doi: 10.1159/000464282. Epub 2017 Jun 13. Review.

34.

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, Ciombor KK, Eyring AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Cope L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader AN, Taube J, Housseau F, Spetzler D, Xiao N, Pardoll DM, Papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Diaz LA Jr.

Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.

35.

Immunosuppressive cell death in cancer.

Hou J, Greten TF, Xia Q.

Nat Rev Immunol. 2017 Jun;17(6):401. doi: 10.1038/nri.2017.46. Epub 2017 May 8. No abstract available.

36.

Treating Hepatobiliary Cancer: The Immunologic Approach.

Duffy AG, Greten TF.

Dig Dis. 2017;35(4):390-396. doi: 10.1159/000456593. Epub 2017 May 3. Review.

37.

Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma.

Duffy AG, Ma C, Ulahannan SV, Rahma OE, Makarova-Rusher O, Cao L, Yu Y, Kleiner DE, Trepel J, Lee MJ, Tomita Y, Steinberg SM, Heller T, Turkbey B, Choyke PL, Peer CJ, Figg WD, Wood BJ, Greten TF.

Clin Cancer Res. 2017 Aug 15;23(16):4633-4641. doi: 10.1158/1078-0432.CCR-16-3171. Epub 2017 May 2.

38.

Systematic evaluation of immune regulation and modulation.

Stroncek DF, Butterfield LH, Cannarile MA, Dhodapkar MV, Greten TF, Grivel JC, Kaufman DR, Kong HH, Korangy F, Lee PP, Marincola F, Rutella S, Siebert JC, Trinchieri G, Seliger B.

J Immunother Cancer. 2017 Mar 21;5:21. doi: 10.1186/s40425-017-0223-8. eCollection 2017. Review.

39.

Liver cancer: Regorafenib as second-line therapy in hepatocellular carcinoma.

Duffy AG, Greten TF.

Nat Rev Gastroenterol Hepatol. 2017 Mar;14(3):141-142. doi: 10.1038/nrgastro.2017.7. Epub 2017 Feb 8. No abstract available.

PMID:
28174418
40.

Tumor regulation of the tissue environment in the liver.

Eggert T, Greten TF.

Pharmacol Ther. 2017 May;173:47-57. doi: 10.1016/j.pharmthera.2017.02.005. Epub 2017 Feb 4. Review.

41.

Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.

Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, Davis JL, Hughes MS, Heller T, ElGindi M, Uppala A, Korangy F, Kleiner DE, Figg WD, Venzon D, Steinberg SM, Venkatesan AM, Krishnasamy V, Abi-Jaoudeh N, Levy E, Wood BJ, Greten TF.

J Hepatol. 2017 Mar;66(3):545-551. doi: 10.1016/j.jhep.2016.10.029. Epub 2016 Nov 2.

42.

Shall we blame CD4 T cells for everything?

Greten TF, Korangy F.

Gut. 2017 May;66(5):763-764. doi: 10.1136/gutjnl-2016-312900. Epub 2016 Nov 1. No abstract available.

43.

The case for immune-based approaches in biliary tract carcinoma.

Duffy AG, Makarova-Rusher OV, Greten TF.

Hepatology. 2016 Nov;64(5):1785-1791. doi: 10.1002/hep.28635. Epub 2016 Jun 18. Review.

44.
45.

Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression.

Eggert T, Wolter K, Ji J, Ma C, Yevsa T, Klotz S, Medina-Echeverz J, Longerich T, Forgues M, Reisinger F, Heikenwalder M, Wang XW, Zender L, Greten TF.

Cancer Cell. 2016 Oct 10;30(4):533-547. doi: 10.1016/j.ccell.2016.09.003.

46.

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards.

Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, Rodriguez PC, Sica A, Umansky V, Vonderheide RH, Gabrilovich DI.

Nat Commun. 2016 Jul 6;7:12150. doi: 10.1038/ncomms12150. Review.

47.

Editorial: "Invisible" MDSC in tumor-bearing individuals after antibody depletion: fact or fiction?

Ma C, Greten TF.

J Leukoc Biol. 2016 Jun;99(6):794. doi: 10.1189/jlb.5CE0116-047R. No abstract available.

PMID:
27252522
48.

Specific immunotherapy in hepatocellular cancer: A systematic review.

Baradaran Noveiry B, Hirbod-Mobarakeh A, Khalili N, Hourshad N, Greten TF, Abou-Alfa GK, Rezaei N.

J Gastroenterol Hepatol. 2017 Feb;32(2):339-351. doi: 10.1111/jgh.13449.

49.

Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer.

Duffy AG, Makarova-Rusher OV, Ulahannan SV, Rahma OE, Fioravanti S, Walker M, Abdullah S, Raffeld M, Anderson V, Abi-Jaoudeh N, Levy E, Wood BJ, Lee S, Tomita Y, Trepel JB, Steinberg SM, Revenko AS, MacLeod AR, Peer CJ, Figg WD, Greten TF.

Int J Cancer. 2016 Oct 1;139(7):1648-57. doi: 10.1002/ijc.30199. Epub 2016 Jun 27.

50.

Population attributable fractions of risk factors for hepatocellular carcinoma in the United States.

Makarova-Rusher OV, Altekruse SF, McNeel TS, Ulahannan S, Duffy AG, Graubard BI, Greten TF, McGlynn KA.

Cancer. 2016 Jun 1;122(11):1757-65. doi: 10.1002/cncr.29971. Epub 2016 Mar 21.

Supplemental Content

Loading ...
Support Center